Media » University of Liverpool and University of Washington forge the way in revolutionary long-acting medicines

University of Liverpool and University of Washington forge the way in revolutionary long-acting medicines

Geneva, 31 January 2020 – The Medicines Patent Pool (MPP) congratulates the University of Liverpool (UoL) and the University of Washington (UoW) on receiving each a Unitaid grant to lead revolutionary long-acting medicines research.The LONGEVITY project led by the UoL aims to develop long-acting formulations for malaria and TB prevention, and a single-injection cure for hepatitis C. The GLAD project led by the UoW seeks to reduce HIV transmission and resistance to HIV drugs and improve the quality of life of those taking them through long-acting treatment regimens.

MPP is proud to partner with both projects and to use its expertise and model to address access barriers early in the development cycle and, to provide a pathway for low- and middle- income countries to promptly obtain these new products. With its recognised expertise in intellectual property-related facilitation, MPP will engage with the different stakeholders to secure partners in accelerating access to affordable quality revolutionary long-acting treatments in the countries where they are needed.

Access Unitaid’s statement

Access the University of Liverpool’s statement

More about the University of Washington’s long-acting HIV medicines’ program

 

More information on the MPP and Unitaid intellectual property report on long-acting technologies

This website uses cookies to ensure you get the best experience on our website. Learn More